Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Long-Term Investments for 14 consecutive years, with $335.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments changed N/A to $335.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $335.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $335.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments for Q4 2025 was $335.0 million at Cytokinetics, up from $288.8 million in the prior quarter.
  • The five-year high for Long-Term Investments was $335.0 million in Q4 2025, with the low at $10.7 million in Q2 2022.
  • Average Long-Term Investments over 5 years is $120.0 million, with a median of $73.7 million recorded in 2021.
  • The sharpest move saw Long-Term Investments crashed 85.52% in 2022, then surged 1640.16% in 2024.
  • Over 5 years, Long-Term Investments stood at $152.0 million in 2021, then crashed by 69.28% to $46.7 million in 2022, then dropped by 13.22% to $40.5 million in 2023, then skyrocketed by 564.05% to $269.2 million in 2024, then rose by 24.48% to $335.0 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $335.0 million, $288.8 million, and $178.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.